PolyPeptide Group AG (PPGN) - Total Liabilities
Based on the latest financial reports, PolyPeptide Group AG (PPGN) has total liabilities worth CHF442.08 Million CHF (≈ $558.91 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PolyPeptide Group AG - Total Liabilities Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's total liabilities have evolved over time, based on quarterly financial data. Check PolyPeptide Group AG (PPGN) asset resilience to evaluate the company's liquid asset resilience ratio.
PolyPeptide Group AG Competitors by Total Liabilities
The table below lists competitors of PolyPeptide Group AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
China | CN¥2.48 Billion |
|
TPK Holding Co Ltd
TW:3673
|
Taiwan | NT$49.32 Billion |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
China | CN¥228.13 Million |
|
Grocery Outlet Holding Corp
NASDAQ:GO
|
USA | $2.11 Billion |
|
Solomon Technology Corp
TW:2359
|
Taiwan | NT$3.83 Billion |
|
Onechance
SHE:300792
|
China | CN¥138.44 Million |
|
Yieh Phui Enterprise Co Ltd
TW:2023
|
Taiwan | NT$66.43 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down PolyPeptide Group AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PolyPeptide Group AG asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.39 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PolyPeptide Group AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PolyPeptide Group AG (2018–2024)
The table below shows the annual total liabilities of PolyPeptide Group AG from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF399.33 Million ≈ $504.86 Million |
+29.71% |
| 2023-12-31 | CHF307.86 Million ≈ $389.22 Million |
+99.77% |
| 2022-12-31 | CHF154.10 Million ≈ $194.83 Million |
-11.37% |
| 2021-12-31 | CHF173.87 Million ≈ $219.81 Million |
-12.33% |
| 2020-12-31 | CHF198.31 Million ≈ $250.72 Million |
+27.35% |
| 2019-12-31 | CHF155.73 Million ≈ $196.88 Million |
+14.38% |
| 2018-12-31 | CHF136.15 Million ≈ $172.13 Million |
-- |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more